Population pharmacokinetics and personalized dosing strategy of biapenem

Population pharmacokinetics and personalized dosing strategy of biapenem: a retrospective study of 2018-2022

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300073976

Enrollment

Unknown

Registered

2023-07-26

Start date

2023-08-01

Completion date

Unknown

Last updated

2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious diseases

Interventions

Observational group:None

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Hospitalized patients treated by biapenem during 2018.1.1 -2022.12.31 2. Treated by parenteral biapenem over 3 days ; 3. Biapenem serum concentration determined during treatment

Exclusion criteria

Exclusion criteria: 1. Incomplete data 2. Age < 18 years old

Design outcomes

Primary

Measure	Time frame
Serum concentration of biapenem;	—

Secondary

Measure	Time frame
Serum creatinine;Albumin;Blood urea nitrogen;White blood cell;	—

Countries

China

Contacts

Public ContactDayu Chen

Nanjing Drum Tower Hospital

cdy_pharmacy@njglyy.com+86 159 5191 6689

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026